<DOC>
	<DOC>NCT00626236</DOC>
	<brief_summary>It is hypothesized that, when given at the lowest effective dose, the favorable side effect profile combined with it's lower propensity for weight gain would make SPN-810 a candidate for treatment of persistent serious conduct problems in pediatric subjects with ADHD.</brief_summary>
	<brief_title>Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<criteria>1. Healthy pediatric male or female subjects, age 6 to 12 years. 2. Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSMIVTR) diagnosis of ADHD. 3. NCBRFTIQ disruptive behavior disorder subscale 27 or greater at baseline; AND a score of 2 or more on at least 1 of the following 3 items of the conduct problem subscale: knowingly destroys property, gets in physical fights, physically attacks people. 4. IQ greater than 71. 1. Current or lifetime diagnosis of bipolar disorder, posttraumatic stress disorder, personality disorder, or psychosis not otherwise specified. 2. Currently meeting DSMIVTR criteria for major depressive disorder, obsessive compulsive disorder, or pervasive developmental disorder. 3. Any other anxiety disorder as primary diagnosis. 4. Use of anticonvulsants, antidepressants, lithium, carbamazepine, valproic acid, or cholinesterase inhibitors within 2 weeks of baseline. 5. Unstable endocrinological or neurological conditions which confound the diagnosis or are a contraindication to treatment with antipsychotics.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ADHD and conduct problems</keyword>
</DOC>